| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T430 |
0-25 |
Sentence |
denotes |
Sunitinib malate (Sutent) |
| T431 |
26-72 |
Sentence |
denotes |
(Pfizer) Bioavailability not affected by food; |
| T432 |
73-119 |
Sentence |
denotes |
after oral dosing, Cmax observed 6-12 h (Tmax) |
| T433 |
120-130 |
Sentence |
denotes |
Vd= 2230 L |
| T434 |
131-152 |
Sentence |
denotes |
(substrate for ABCB1) |
| T435 |
153-280 |
Sentence |
denotes |
(184) Metabolized mainly by CYP3A4 50 mg orally once daily (4 weeks on, 2 weeks off); 37.5 mg orally (continuous daily dosing); |
| T436 |
281-444 |
Sentence |
denotes |
95% binding for sunitinib, 90% binding for sunitinib’s primary metabolite (HSA) Dyspnea and cough have been reported in association with sunitinib treatment (229); |
| T437 |
445-509 |
Sentence |
denotes |
there are no reports of sunitinib treatment-induced pneumonitis. |
